Thienopyrimidinone NMDA receptor modulators and uses thereof
US10973825B2 · kind B2 · utility
6Cited by
2References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2016 |
| Grant date | Apr 13, 2021 |
| Priority date | — |
| Expiry date | Feb 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.